NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ:PSTI); (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company has received certification that its manufacturing facility in Haifa, Israel has been approved as a Good Manufacturing Practices (GMP) standard site for the purpose of manufacturing PLX cells which will be shipped to the EU for use in the Company’s upcoming clinical trials. Pluristem was awarded this certification by Biotec Distribution Wales, Ltd., the designee of the Paul Ehrlich Institute, the EU equivalent to the FDA, to monitor the import, certification, labeling, storage and distribution of PLX cells into the EU for clinical trials. PLX cells are Pluristem’s placental-derived mesenchymal stromal cells (MSCs) that have been expanded in the Company’s proprietary PluriX™ 3-D bioreactor.
